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1. Introduction
Penile squamous cell carcinoma (PSSC) is an uncommon malignant tumor, which accounts
for less than 1% of adult male cancers in North America and Europe, but is markedly higher
in developing locations, such as Asia, Africa and South America, representing up to 10% of
tumors in men. Human papillomavirus (HPV) infection has shown an important role in
penile cancer pathogenesis. In 2009, a systematic review of published literature found that
40% of penile tumors were HPV-related, and that type 16 HPV was the most common subtype
in this group (Backes et al., 2009). Another interesting relation between HPV infection and
penile  cancer  is  the  finding  that  specific  histological  subtypes  are  associated  with  HPV
infection. Penile carcinomas with basaloid differentiation and warty features have shown a
strong association with HPV infection, with recent studies showing that HPV infection is
present in 76% of basaloid tumors, while the presence in verrucous cancer was 24.5% (Backes
et al., 2009).
The recent literature suggests that the oncogenic potential of HPV integration into host DNA
genome and their ability to manipulate cell cycle regulators is responsible for the establishment
and maintenance of HPV genomes in the squamous epithelium and HPV-related PSCC cancer,
which will result in deregulated expression of oncoproteins such as E6 and E7. The oncoprotein
E6 is known to induce degradation of the tumor suppressor protein p53 and the oncoprotein
E7 binds to retinoblastoma protein (pRb). Thus, the oncoproteins E6/E7 allow cells to evade
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cell cycle checkpoints and to entrance in S1 phase of cell cycle, leading to disruption of normal
cell cycle controls.
Following cell division, infected cells leave the basal layer, migrate towards the suprabasal
regions and begin to differentiate. Increased understanding of cervical pathogenesis has led to
confirmation of HPV as an etiological agent for several cancers and consequently to the
development of preventive vaccines targeting HPV antigens for the control of HPV-related
cancers. HPV vaccine was developed as a result of the achievement of core technologies, that are
able to produce virus-like particles (VLPs), which, in turn, are able to mimic the natural virus
and elicit high-titers of virus neutralizing antibodies. With the progress through advanced stages
of clinical trials and further exploration of combinatorial strategies, there is a great promise for
significant advances also in the field of therapeutic HPV vaccine development, not only to cervical
cancer, but other several malignancies related to HPV infection. Moreover, in this chapter we
discuss the current status of HPV vaccines as well as the most common associated factors that
might interfere on establishment of strategies that could control the HPV infections and the
development of penile carcinoma associated to this infection.
2. Penile cancer
Penile malignancies are thought to arise from the accumulation of multiple mutations that may
occur as consequence of progressive genetic instability. This intricate process of genetic
instability may be caused by environmental factors, such as history of intense smoking, penile
tears, phimosis, and poor genital hygienic habits. (Chaux & Cubilla 2012). In addition, a recent
study conducted by Chaux et al. (2011) also described the poor education, penile chronic
inflammation, genital warts and Human papillomavirus (related to number of sexual partners
during lifetime) as environmental factors to malignant transformation.
There is a worldwide geographic difference in occurrence of penile malignancies that could
be caused by differences in socio-economic status, cultural and religious conditions (Bleeker
et al. 2009, Chaux & Cubilla, 2012). The higher incidences are frequent in tropical or subtropical
regions of Latin America, Asia and Africa but have uncommon incidence rates in Europe,
Japan, USA and Israel (Cubilla 2009). Recently, were reported higher incidence rates in
underdeveloped regions such as Africa, South America, and Asia (2-4/100000 inhabitants) as
compared with North America (United States) and Europe (0.3-1/100000 inhabitants) (Chaux
& Cubilla, 2012). Pow-Sang et al. (2010) also described the penile malignancies prevalence rate
among different populations. Prevalence rates in developed countries as Israel (0.1/100 000)
and United States (0.3-1.8/100 000) and interestingly, compared with underdeveloped coun‐
tries such as Uganda (2.8/100 000) and Brazil (1.5-3.7/100 000). Once again confirming the
disease geographical difference and the influence of country development.
Squamous cell Carcinoma represents vast majority of histological subtype of primary penile
malignancies with heterogeneous features due to differences in morphology pathogenesis and
prognosis (Hakenberg & Protzel, 2012; Stankiewicz et al., 2012; Syed et al., 2012). Knowledge
Human Papillomavirus and Related Diseases – From Bench to Bedside A Diagnostic and Preventive Perspective222
of origin and progression of penile squamous cell carcinoma depends on an intricate relation
between anatomy and histopathology.
The anatomy of the penis is complex and has important implications to define predictive risk
model and delineate the prognostic factors (Chaux & Cubilla, 2012). The same authors
described 3 anatomical compartments in the penis (Glans, Foreskin and Coronal Sulcus) where
the malignant neoplasms may be originated (Fig 1). However, the penile malignant neoplasms
have a predilection to originate first on the Gland followed by Foreskin inner mucosa and lastly
the Coronal Sulcus is rarely affected by neoplastic entity.
Figure 1. Paraurethral longitudinal section presenting anatomical levels of the Penis. CC: Corpus Cavernosum; CS: Cor‐
pus Spongiosum; LP: Lamina Propria; SF: Skim of the Foreskim and TA: Tunica Albuginea. (Adapted from Chaux & Cu‐
billa 2012).
Recently, Hernandez et al. (2008) performed an epidemiological study with 4967 United States
men with the diagnosis of penile squamous cell carcinoma. Thirty four percent of patients
(1712) presented neoplasms arising in gland, 13.2% in prepuce, 5.3% in penis shaft, 4.5%, in
overlapping of penis, and 42,5% in unspecified site. Lesions generally initiate on the glans and
slowly extend to involve completely the glans and shaft of the penis. During the neoplasm
progress Buck’s fascia act as a natural barrier to local tumor invasion defending the corporal
bodies from tumoral expansion (Pow-Sang et al. 2010). This assessment is schematically
illustrated in figure 2.
The anatomy of the penis presents a pivotal role in tumor invasion and prognosis of cancer.
Moreover, the TNM staging system is based, at least partially, on the commitment of these
anatomical levels (Velazquez et al. 2010). The glans can be divided in 4 levels: squamous
epithelium, lamina propria, corpus spongiosum, and corpus cavernosum (corpus spongio‐
sum, and corpus cavernosum are subdivided by the tunica albugínea). Anatomical levels in
the foreskin, like in glans, are divided in squamous epithelium, lamina propria, dartos muscle,
and outer skin (Chaux & Cubilla, 2012).
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A previous study suggests that different tumor histological features could be based on
anatomical site. This hypothesis is sustained by the histological differences among the urethral
segments and their corresponding neoplasms (Velasquez et al. 2005). As discussed previously,
Squamous Cell Carcinoma of Usual Type (SCCUT) is the most frequent histopathologic
diagnoses in penile malignancies (Chaux & Cubilla, 2012; Stankiewicz et al. 2012) affecting
around 48%-65% of all type of penile carcinoma. Additionally, Epstein et al. (2011) reported
11 more subtypes of SCCUT (Table 1). Macroscopic features of SCCUT range from endophytic
to irregular exophytic masses, presenting white-to-gray coloration. However, the reddish
pigmentation also can be observed (Chaux et al. 2010). Microscopilly, the SCCUT is similar to
oral, vulvar and cervical Squamous Cell Carcinomas (Cubilla et al. 2001). SCCUT may vary
from well-differentiated tumors to anaplastic entities. Other presented feature is keratiniza‐
tion, ranging from highly keratinized, presented in well-differentiated tumors, until scarce or
minimal keratinization observed in anaplastic neoplasm. Chaux et al. (2010)
Evidences from pertinent literature indicate the involvement of groin lymph nodes as the most
relevant and unfavorable prognostic factors predicting cancer-specific survival in patients
with penile squamous cell carcinoma. Numerically, in the same review, the 5-year cancer-
specific survival rate for those presenting cN0 tumors were between 75% and 93%, compared
with a 5-year cancer-specific survival rate for those presenting cN3 tumors ranging between
20% and 34%. There is a substantial decrease in the survival rates with N progression (Novara
et al. 2007).
Figure 2. Natural history of penile cancer (Adapted from Pow-Sang et al. 2010).
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Lopes et al. (2002) performed a study that aimed to investigate the p53 in Brazilian patients
with PSCC to establish a new prognostic factor for lymph node metastasis and its possible
influence on prognosis. This study observed the nodal stage as a factor that influenced survival
(independent risk factors) in the univariate and multivariate analyses. Gunia et al. (2012)
shown that p16INK4a is a good prognostic marker for penile squamous cell carcinomas,
surpassing the prognostic impact of histologically confirmed koilocytosis. In their study,
p16INK4a expression predicted better cancer specific survival rates. Furthermore, p16INK4a
can be useful in differentiate subtypes of PSCC. According Chaux & Cubilla (2012), warty
carcinomas tend to be p16INK4a positive, whereas giant condylomas and papillary and
verrucous carcinomas are consistently negative.
Medical record analysis of 145 men with penile squamous cell carcinomas was performed to
identify prognostic factors for lymph node involvement (Lopes et al. (1996)). The authors found
that lymph node metastasis presents correlation with tumor thickness, lymphatic and vascular
embolization. Interestingly, univariate analysis did not reached statistically significant values
to pathologic stage of primary tumor, clinical lymph node stage (cN), and histological grade.
However, histological grade may be considered an important prognostic factor in penile
squamous cell carcinoma. In accord with Cubilla AL. 2009 these prognostic factors are
predictive to the nodal spread, metastasis and tumoral dissemination.
Currently, different methods are employed to grade Penile Squamous Cell Carcinomas. For
instance, Akhter et al. (2011) uses the Broder’s system as histological grade system in Squamous
Cell Carcinoma. In the Broder’s system Penile Squamous Cell Carcinomas is stratified in 4
grades levels based only in differentiation of the cells: Grade I (well differentiated) presenting
<25% undifferentiated cells; Grade II (Moderately differentiated) presenting <50% undiffer‐
Classification of SCCs of the penis
Subtype Frequency (%)
Usual SCC 48-65
Basaloid carcinoma 4-10
Warty carcinoma 7-10
Verrucous carcinoma 3-8
Papillary carcinoma 5-15
Sarcomatoid carcinoma 1-3
Mixed carcinomas 9-10
Adenosquamous carcinoma 1-2
Pseudohyperplastic carcinoma <1
Carcinoma cuniculatum <1
Pseudoglandular carcinoma <1
Warty-basaloid carcinoma 9-14
Table 1. Classification of Squamous Cell Carcinomas (SCCs) of the penis (Adapted from Chaux & Cubilla 2012)
Human Papillomavirus Infection and Penile Cancer: Past, Present and Future
http://dx.doi.org/10.5772/55811
225
entiated cells; grade III (Poorly differentiated) presenting <75% undifferentiated cells and
grade IV (Anaplastic/Pleomorphic) >75% undifferentiated cells. Cell anaplasia degrees are also
pointed as common approach to determine Penile Squamous Cell Carcinomas grading (Mikuz
et al. 2004; Slaton et al. 2001), absence of anaplasia (well differentiated cells), grade 1; grade 2,
moderately differentiated (<50% anaplastic cells); and grade 3, poorly differentiated (>50%
anaplastic cells). Cubilla et al. (2009) reported a method to grade Penile Squamous Cell
Carcinomas. Carcinomas with a minimal deviation from normal/hyperplastic morphology of
squamous epithelium were considered Grade 1 (extremely well-differentiated). Grade 3 are
tumors showing any proportion of anaplastic cells, identified as solid sheets or irregular small
aggregates, cords or nests of cells with little or no keratinization, high nuclear cytoplasmic
ratio, thick nuclear membrane, nuclear pleomorphism, clumped chromatin, prominent
nucleoli and numerous mitosis. Grade 2 is composed by remainder tumors. Grading both
extremes of the spectrum is simple and reproducible.
In summary, Penile Squamous Cell Carcinomas represents an aggressive locoregional
malignancy with dissemination process may occurring 20-40% (Guimarães et al. 2009), a lethal
disorder that often presents after significant delay (Barocas & Chang 2010). Usually, death
occurs within 2 years after initial diagnosis (Guimarães et al. 2009). Accurate evaluation of
clinical stage, anatomical site, regional lymph nodes, and metastatic disease presents a pivotal
role in treatment planning to predict the survival outcome (Barocas & Chang, 2010).
3. HPV
Papillomaviruses are a family of pathogens that infect exclusively the epithelial tissues of
amphibians, reptiles, birds and mammals (Franceschi, 2005). The viruses are grouped accord‐
ing to the anatomic site of infection and their preference for either cutaneous or mucosal
squamous epithelium. The cutaneous types, or beta papillomaviruses, are usually found in the
general population and cause common warts. In contrast, the alpha, or mucosotropic, papil‐
lomaviruses have been implicated in mucosal infections (Snow & Laudadio, 2010; Vidal &
Gillison, 2008). The mucosotropic group of human papillomavirus comprises 15 species and
infects the anogenital tract, upper aerodigestive tract and other head and neck mucosa (Chow
et al., 2010). Because they are sexually transmitted and play important roles in diseases, these
viruses have received much attention and research and clinical investment (Chow et al., 2010).
As molecular virology is depicted in details in another chapter, here we will only cover penile
cancer-related aspects. Currently, over 200 HPV genotypes have been identified (Wang et al.,
2012). HPVs with a high affinity for mucosal sites can be classified into non-oncogenic, or low-
risk, types or as potentially oncogenic, or high-risk, types. Mucosal and genital HPVs can be
divided into low-risk (HPVs 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81) and high-risk (HPVs 16, 18,
31, 33, 35, 51, 52) types according to their presence in malignant lesions (Bosch et al., 2002;
Muñoz et al., 2003).
The multiplicity of functions of the small papillomavirus oncoproteins, E5, E6 and E7,
continues to be studied through last decades, although there are several mechanisms well
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established. Specifically, more than a dozen protein-protein interactions between E6 and
cellular proteins have been shown (Villa et al., 2002). Taken into a carcinogenic point of view,
E6 and E7 ORF are considered to play the most important roles, encoding for oncoproteins
that allow viral replication and the immortalization and transformation of the epithelial cell
that host the HPV DNA (Doorbar et al., 1991).
Proving the importance of p53 and pRb in cell cycle progression, the repression of HPV 16 E6
and E7 expression by dual shRNA transfection has been shown to be capable of restoring the
p53 and pRb tumor suppressor pathways and activating apoptosis (Psyrri et al., 2009, Rampias
et al., 2009). Thus, the demonstration of this tumor suppressor inactivation by the E6 and E7
HPV oncoproteins has provided a basic explanation for how the high-risk HPV types exert
their oncogenic effects on cervical cells, and this explanation are under investigation to be
related with other sites of HPV-infection. This is particularly important in penile cancer-
associated HPV infection, whereas HPV16 seems to develop a pivotal role, and accounts for
more than 60% of HPV-related tumors.
4. HPV impact in squamous cell homeostasis
Different from other viruses, HPV does not infect or replicate in antigen-presenting cells
(APCs) of the epithelium nor induce cell lysis, which is a key escape mechanism to avoid that
APC recognize and produce antigens derived from the virion, and alerts immune system.
About more than 50% of infections present seroconversion in the patients, but the production
of antibodies usually occurs only months after the initial infection (Vidal & Gillison, 2008). The
life cycle of papillomaviruses is closely tied to the epithelial differentiation process. Infection
occurs exclusively in squamous epithelial cells with a preference for the keratinocyte stem cell
as the initial target of HPV infection, which will allow the maintenance of viral replication
(Vidal & Gillison, 2008). The route of entry for HPV infection is microtraumas or small wounds
in the skin or mucosal surface, which are particularly important in penile HPV-infection. These
breaks in the epithelial surface allow the virus to access and persist in the nuclei of infected
basal layer cells of the epithelium. Until now, no single receptor has been definitively identified
and established as being responsible for HPV entry, although is believed that receptors closely
related to wound healing might be preferential targets for HPV infection, such as α6 integrin
and glycosamioglycan heparin (Vidal & Gillison, 2008).
As most viruses, HPV uses the host cell DNA machinery to maintain the production of viral
progeny. This mechanism of viral-induced cell growth is very well known and is analogous
to other viruses that disrupt the control of cell growth (Hebner & Laimins, 2006). Following
cell division, as the basal cells divide into squamous epithelial cells, HPV establishes its DNA
genome in the host cell nuclei, replicates and reaches a high copy number. Infected cells then
leave the basal layer, migrate toward the suprabasal regions and begin to differentiate. In the
basal layer phase, the HPV genome is maintained at a low copy number, providing a type of
stock of viral DNA for further use in cell divisions. At the same time, ‘early’ viral genes (E5,
E6 and E7) are expressed, resulting in enhanced proliferation of the infected cells and their
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lateral expansion, working to spread infection cells throughout epithelial tissue. While the
basal cells and viral DNA divide, some daughter cells may be maintained in the basal layers,
whereas other daughter cells move toward the upper layers of the epithelium and begin to
differentiate. During this process in which the infected cells enter into the suprabasal layers,
the viral genome replicates to a higher copy number; ‘late’ viral gene (L1 and L2) expression
is initiated; and structural proteins, as such capsid proteins, are formed. Subsequently, virions
are assembled and released as the upper layer of epithelium is shed (Fehrmann & Laimins,
2003; Scheurer et al., 2005; Vidal & Gillison, 2008).
Figure 3. Representation of normal and HPV-infected epithelium according to the cellular differentiation and the dif‐
ferentiation-dependent viral functions (Adapted from Hebner & Laimins, 2006).
This provides an important microenvironment for cellular growth aberrations, and is partic‐
ularly important in penile pre-neoplastic lesions. Several authors have reported a higher level
of HPV detection in PIN, when compared to penile cancer, open field for a HPV importance
in the development of tissue growth abnormalities, leading to a soil field for carcinogenesis.
In this model, HPV would be an important co-factor in penile pre-neoplastic development.
Due to all of his effects in cell growth and lack of cell cycle control, the formation of lesions
such as PIN associated to other important factors in penile carcinogenesis (genera hygiene,
phimosis, chronic inflammation, high number of sexual partners).
5. Prevalence of HPV infection in penile squamous cell carcinoma and
histological considerations
In contrast with the high prevalence of HPV infection in cervix carcinomas, which may be
detected in almost 100% of the cases, in penile carcinomas the detection is considerably lower,
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although it stills an important in penile pathogenesis. According to the current evidences,
penile cancer can follow 2 distinct etiologic pathways: one is related to environmental factors,
such as phimosis, smoking, poor personal hygiene and chronic inflammation; and other one
is the HPV-related penile cancer (Rubin et al., 2001; Cubilla et al., 2010). Several studies have
highlighted the prevalence of HPV infection in penile cancer, with an average prevalence of
47% to 48% in more than 60 studies (Backes et al., 2009; Miralles-Guri et al., 2009). Differently
from cervix cancer, in penile cancer the prevalence of HPV infection varies according to
histological subtypes, being strongly prevalent in basaloid and warty carcinomas, and lesser
prevalent in keratinizing variants, such as verrucous, papillary and usual carcinomas
(Guimarães et al., 2011). Before understanding the relationship between HPV and specific
histological subtypes, a basic knowledge of penile cancer histology is required.
Squamous cell carcinoma of the penis is currently divided in 12 subtypes. Each one of this
subtypes shows distinctive outcomes, and this high number of subtypes makes its difficult to
characterize the disease. About half of penile cancers are of the usual squamous histology,
while the rest is divided through the special types.
Basaloid carcinomas: represent 4-10% of penile tumors. Macroscopically, these tumors show
an ulcerative aspect, presenting as a solid, firm invasively neoplasm, with necrosis foci.
Microscopically, they present a nesting pattern, with each nest presenting a solid or central
necrotic nest (comedonecrosis). Keratinization can be observed, although not pathognomonic.
Cells presents as small, basofilic, basaloid, spindle or pleomorphic, with abundance of mitotic
and apoptotic figures. Perineural and vascular invasions are often seen.
Warty carcinomas: represent 7-10% of all cases. It can be described as verruciform tumors,
with an exoendophytical appearance, although a rare non-invasive exophytic tumor may be
found. Histologically, a classical condylomatous papilla is observed, with a arborescent
pattern, a central fibrovascular core, and keratinized cells, with presence of superficial and
deep pleomorphic koilocytosis. Different from giant condillomas, in warty carcinomas these
cells are typically malignant. Also, as a differential diagnosis, low-risk HPV or negative
p16INK4a status favors a condilloma diagnosis. Prognosis is often good, with no signs of nodal
involvment, although it might be present in deep invasive warty carcinoma (Chaux & Cubilla,
2012).
Verrucous carcinomas: represent 3-8% of the cases. Macroscopically are classically character‐
ized by exophytic, verrucoid white lesion, with a clear base separating them from the stroma.
Microscopically, they are acanthotic, papillomatous neoplasms, with a high degree of difer‐
entiation. As most well differentiated tumors, they have a good prognosis, only presenting
metastasis when they present areas with poor differentiation. However, if it presents large
areas of undifferentiation, the tumor is classified as a mixed verrucous carcinoma, as the
classical verrucous carcinoma is a classicaly well differentiated tumor.
Papillary carcinoma: represent 9-10% of all cases. It is also a verruciform tumor, diagnosed
after excluding the possibility of a verrucous or warty tumor. Macroscopically is observed as
an exophytic large tumor, with a clear jagged interface with stroma. Microscopically, papillo‐
matosis is observed and a low-grade histology is present. Different from verrucous carcinoma,
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acanthosis is not so prominent, and differently from warty carcinoma, there is no koilocytosis.
They have an excellent prognosis with very infrequent metastasis.
Sarcomatoid carcinomas: correspond to 1-3% of cases. Macroscopically, they are hemorrhagic
and necrotic, or polypoid tumors. Microscopically, they can mimic several sarcomas, like
leiomyosarcomas, osteosarcomas, or fibrosarcomas. They are observed as tumors with two
different cellular presentations, with the presence of epithelial and spindle cells. They are
typically located in glans, not in corpora cavernosa, and may present foci of associated penile
intraepithelial neoplasia. Immunohistochemical stains with high-molecular-weight cytokera‐
tins and p63.
Other mixed tumors are often rare, which makes very difficult to establish their relationship
with HPV infection, and comprises several subtypes, such as Pseudohyperplastic Carcinoma,
Carcinoma Cunilatum and Pseudoglandular Carcinoma.
As stated before, distinct pathological variants of PSCC are associated with an indolent
behavior (eg, verrucous, warty and Buschke-Lowenstein condyloma) and other with more
aggressive forms (eg, usual SCC, basaloid and papillary). For basaloid and warty carcinomas,
the HPV-infections are present in 80-100% of all cases. It is important to remember that in
situ SCC seems to be strongly related with HPV-infection (Kayes et al., 2007). Seems plausible
then that HPV-infection is far more important as a co-factor that will prepare the soil for a
neoplastic malignant transformation, due to the several pathways in which HPV-infection
contributes. This is in accordance with the theory of two major pathways in penile cancer
development, being one driven by factors such as poor hygiene, presence of phimosis, chronic
inflammation, etc), and another one driven by high-risk HPV-infection (Rubin et al., 2001). As
discussed above, this represents an astonishing opportunity for a new approach to prevent
this disease, as HPV vaccination researches are under constant evolution. As a health problem,
the prevention of HPV infection might be able to avoid the development of these subtypes of
HPV in men, if the current knowledge of HPV-driven malignancy is right.
6. HPV-status impact on outcome in penile carcinomas
Although there are not many studies investigating a prognostic role for HPV-infection in penile
carcinomas, some studies maintain HPV as a controversial factor, in terms either of survival,
or local metastasis, and lymph node involvement. From the three more important studies, it
is still unknown if HPV alone may have an impact in penile cancer`s patients overall survival,
as demonstrated in several other solid tumors, such those arising in oral cavity and oropharynx
(Lont et al., 2006). In a study conducted by Cubilla et al. (2010), HPV-16 was the most prevalent
genotype (72% of all cases), followed by HPV-6 (9%) and HPV-18 (6%). The 16 and 18 genotype
(high-risk HPV types) were proposed to be associated with aggressive variants of penile
tumors, and to be associated with a poorer outcome in these patients. In several studies, the
role of HPV infection in penile cancer could only be observed by indirect means, as the
observation that HPV-infected PSCCs were those with more aggressive subtypes, as basaloid
and warty tumors. So, it is believed that HPV-infection, specially related to HPV-16 and -18,
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represented a more aggressive subtype, with a worst survival when compared to HPV-
negative PSCCs. But directly comparing HPV expression and survival curves, the most
extensive study on high-risk HPV infection was carried out by Lont and colleagues, whom
had demonstrated that penile tumors presenting high-risk HPV infection had a better outcome
from those tumors where high-risk HPVs were not detected. Interestingly, HIV infection did
not correlated (Lont et al., 2006).
7. HPV vaccine
In many countries, vaccines against some HPV types are administered to girls and young
women with the goal of protecting them against HPV-induced cervical cancer (Villa et al.,
2005; Muñoz et al., 2010). The introduction of HPV vaccines has also drawn more attention to
the fact that HPV is associated not only with cervical cancer and genital warts but also with
other tumors, such as head and neck and anogenital cancers (Zur Hausen, 2006).
Although the majority of HPV vaccine research has focused on cervical cancer, some vaccine
developers have targeted other diseases related to different strains of HPV.
Emerging results from vaccine trials have suggested that some cross-protection is possible.
Vaccines against cervical cancer also have the potential to prevent other cancers that are caused
by the same types of HPV (Herrero et al., 2003, Kreimer et al., 2005), and half or more of
anogenital cancers outside the cervix, including cancer of the vulva, vagina, penis, and anus
(Daling et al., 2005, Gross & Pfister 2004). Theoretically, these vaccines should also work against
the same viruses at other anatomical sites, which would be of great value for the majority of
the patients. Since different HPV-related diseases have share the same contamination basis
(eg, HPV contamination in sexual act may happen in anogenital, cervical and even in head and
neck areas. Also, almost all HPV-related tumors share individual at risk with the same
behavior, and it is believed that this prevent potential directed to several organs could reduce
the prevalence of several tumors simultaneously. If proven to do so, this approach would
represent a major conceptual breakthrough, not only in prevention of these diseases, but
equally importantly, by providing the ‘missing link’ in the chain of evidence for the final proof
of HPV etiology in these tumors (Syrjänen, 2010).
8. The HPV prophylactic vaccines
The current HPV prophylactic vaccines are based on VLPs, with two prophylactic HPV
vaccines being commercially available: the bivalent (HPV 16/18) vaccine Cervarix® (GlaxoS‐
mithKline, Middlesex, UK) and the quadrivalent (HPV 6/11/16/18) Gardasil® (Merck, NJ,
USA). Licensed globally, these two vaccines have produced great expectations that they will
prevent infections and tumors induced by different HPV types (Syrjänen, 2010).
The US Food and Drug Administration (FDA) approved Gardasil for females aged 9–26 in
2006. In October 2009, the FDA approved Cervarix for use in females aged 10–25 and approved
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Gardasil for use in males aged 9–26 to prevent genital warts and to prevent the spread of
cervical cancer. Moreover, the FDA (2010 and 2010a) has proclaimed that the dosing and
administration schedule should be 0.5 mL administered intramuscularly (preferably in a
deltoid muscle) on a 3-dose schedule. The second dose should be administered 1 to 2 months
later, and the third dose should be administered 6 months after the first dose.
Although clinical trials of Gardasil and Cervarix have been extremely promising, these first
generation VLP vaccines may not be the ideal vaccine candidates, especially in already infected
patients, and older men and women.
The most recent report from Quadrivalent Human Papillomavirus Vaccine presents important
facts about immunization practices, and provides excellent results. The efficacy for prevention
of HPV 6-, 11-, 16- and 18-related genital warts was 89.3%, as a profilatic vaccine from those
who have take 3 doses and was seronegative at day 1. From males who have received only one
dose, regardless of serology or previous infection was of 68.1%. This efficacy was also con‐
firmed by several other trials in female patients, with >98% efficacy in preventing HPV 6-, 11-,
16- and 18-related grade 2 or 3 cervical intraepithelial neoplasia or adenocarcinoma in situ(CDC
MMWR, 2011).
Another important issue in vaccination process is to determine who are the individuals in more
risk populations, in order to a better efficacy, and a reduction of the high costs involved in the
vaccine production and distribution. Based on incidence of HPV-infection between several
groups, the probabilities of being infected, especially subtypes 16 and 18, are higher in men
who have sex with men (MSM) group than in heterosexual men (Heiligenberg, 2010). Several
diseases have a higher incidence in MSM group, such as anal intraepithelial neoplasia (AIN),
anal cancers, and genital warts (Jin et al., 2007). Another important group which might be
benefited by HPV immunization is the HIV-positive patients, although it is not clear whether
the immunization could provide a long time antibody titers against HPV 6, 11, 16, and 18, and
how immunossupressed patients would react to HPV4 vaccine, in terms of safety and
adversely reactions. However, as HPV4 is not a live vaccine, it can be safely administered to
person in the most highly risk, such as immunocompromised individuals (like HIV-positive,
drug-driven immunossupression, or disease-related immunossupression).
Researchers are now actively working to better develop prophylactic HPV vaccines that may
be effective against a broader range of HPV types and have a longer shelf life.
9. The HPV therapeutic vaccines and its perspectives
Immunotherapy offers an attractive alternative treatment strategy because it can address both
the underlying HPV infection and the visible lesions. Moreover, immunotherapy can target
all HPV-associated lesions, regardless of location, and induce long-lasting immunity, thus
preventing recurrence (Chu, 2003; Stanley, 2012).
A judgment of whether therapeutic HPV vaccine candidates have a real effect on disease has
been difficult because most trials have not been placebo-controlled, and more important, it
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stills not clear for how long these patients can maintain high levels of immune response, as
they have been already infected. The vaccines have also shown, at best, limited efficacy in
eradicating established tumors, although the fact that they have mostly been tested in ad‐
vanced stage cancer patients with compromised immune systems may have limited their
impact (Brinkman et al., 2005).
Perhaps the ideal HPV vaccine strategy calls for a vaccine that possesses both prophylactic
and therapeutic properties. A chimeric vaccine of this type could both prevent new HPV
infections and clear existing infections. Moreover, such a vaccine would benefit and could be
administered to both sexually inexperienced young individuals and older individuals who
already harbor HPV (Franceschi, 2005). Of course the costs of the rise of individuals been
vaccinated needs to be estimated, in order to not turn HPV vaccine in an expensive waste of
health budget. It is important to remember that although some groups are in risk group, not
all individuals of this risk group will develop an HPV-related cancer. So, before implementing
HPV vaccination to a wide range of patients, it needs to be better classified what populations
should be included in vaccination process, and further develop new guidelines to better
incorporate in this vaccination individuals that, even in risk groups, still have a higher risk in
HPV-infection and spread. Opportunities for primary and secondary prevention should be
assessed, including the use of HPV vaccines to prevent infection and therapeutic vaccines in
the adjuvant setting for locoregional recurrence and distant disease (Marur et al. 2010).
Combined with the fact that no therapeutic vaccines currently exist for other diseases, this goal
makes therapeutic HPV vaccine development a challenging task.
The most recent report from Quadrivalent Human Papillomavirus Vaccine (HPV4) presents
important facts about immunization practices, and provides excellent results. The efficacy for
prevention of HPV 6-, 11-, 16- and 18-related genital warts was 89.3%, as a profilatic vaccine
from those who have take 3 doses and was seronegative at day 1. From males who have
received only one dose, regardless of serology or previous infection was of 68.1%. This efficacy
was also confirmed by several other trials in female patients, with >98% efficacy in preventing
HPV 6-, 11-, 16- and 18-related grade 2 or 3 cervical intraepithelial neoplasia or adenocarcinoma
in situ (CDC MMWR, 2011).
10. Final considerations
Several aspects still remain to be discovered in the field of penile cancers and HPV infection,
and although last decade researches were not able to define a causal role for HPV-infection,
several progresses have being made in this matter. The genomic detection of HPV DNA,
primarily in some subtypes of PSCCs, provides stronger support for a viral etiology in this
disease, and corroborates the idea that there are at leas 2 main pathways in penile carcino‐
genesis, and one of them is closely related to HPV.
Targeted therapy for PSCCs now demands more predictive biomarkers, such as the HPV
infection status and mutation status of crucial genes, which could contribute to personalized
treatment for each individual and decrease the inherent morbidities. However, for a better
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understanding of whether the HPV status of tumors has real therapeutic implications in
affecting the clinical outcome, upcoming clinical trials should be significantly standardized in
their design and performed on PSCC, which have been adequately selected and classified with
respect to the different penile carcinoma subtypes. Moreover, we suggest that a more defined
consensus in the histological classification in PSCCs should be utilized to improve HPV
detection and provides means to compare studies in different populations. This is highly
remarkable as is now fully accepted that penile carcinogenesis is quite dependent of local
characteristics, and varies worldwide.
We believe that the increasing effects of HPV vaccination in several cancers could help to
reduce the number of new PSCC cases, especially in developing countries, with a lower
income, and less educated individuals. Although detection of the true effects of HPV vacci‐
nation on cancer incidence will probably continue for several decades, monitoring the current
effects of HPV vaccination is crucial, not only in cervical cancer, but also in penile cancer.
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